Janssen Research & Development, LLC has partnered with Myriad Genetics, Inc. to use its BRACAnalysis test in connection with Janssen’s Phase III trial of Yondelis (trabectedin) in advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers. Specific terms were not disclosed.
"We are delighted to be collaborating with Janssen and applying our more than 20 years of BRCA-testing experience to help advance clinical cancer research," said Mark C. Capone, president of Myriad Genetics Laboratories. "A key element of our business strategy is to partner with major pharmaceutical companies to establish BRACAnalysis as the leading companion diagnostic and this partnership is yet another important step toward that goal and the era of precision medicine and personalized healthcare."
Myriad Genetics, Janssen in Cancer Research Pact
By Kristin Brooks
Published December 9, 2013
blog comments powered by Disqus